gene editing

Computational and AI-Driven Ecosystem for Structure-Based Covalent Drug Discovery.

ConspectusThe field of covalent drug discovery has witnessed a remarkable resurgence in recent years, a trend underscored by the approval of more than 125 covalent drugs by the US FDA as of 2025, which demonstrates their immense therapeutic potential. Driven by ever-increasing computational power and vast amounts of data, deep learning (DL) is profoundly transforming numerous fields, from natural language processing to drug discovery. In the development of covalent drugs, in particular, advanced computational methods centered on data-driven approaches and artificial intelligence (AI) exhibit immense potential. The realization of this potential depends on the construction of a synergistic ecosystem. Here, we define this "ecosystem" as an integrated set of components─including (i) curated covalent-relevant databases, (ii) AI/physics-based predictive and scoring models, (iii) interoperable computational workflows spanning site identification, docking/virtual screening, and lead optimization, and (iv) closed-loop feedback that systematically incorporates experimental outcomes to update data resources and refine/validate models. This begins with the systematic collection of past experimental results to build high-quality databases. These databases, in turn, provide the foundation for developing AI-driven computational tools capable of precisely interfacing with and accelerating downstream tasks, such as molecular docking (for generating physically plausible conformations and conducting large-scale virtual screening) and lead optimization. The application of these AI tools not only guides experimental design, but the resulting key data also feed back into and enrich the databases. Furthermore, in the cutting-edge field of covalent drugs, the precise identification of "druggable" covalent sites on target proteins has emerged as another critically important downstream task.In this Account, we describe a computational and AI-driven ecosystem for structure-based covalent drug discovery and highlight our contributions to this field. By explicitly linking databases, models, workflows, and experimental feedback into a single framework, this Account moves beyond a simple inventory of individual tools to instead offer a systematic and panoramic perspective on an integrated ecosystem for covalent drug discovery, driven by data and computational engines including AI. We focus on how this ecosystem systematically addresses the challenges from covalent binding site identification to lead discovery, thereby fundamentally accelerating the development of next-generation covalent therapies. We first articulate the philosophy behind the construction and updating of covalent databases, emphasizing the necessity of high-quality data. Subsequently, we delve into a suite of cutting-edge, AI-driven computational methods, exploring the potential of deep learning in tasks such as molecular docking, covalent binding site prediction, and lead optimization. To bridge the gap between computational theory and experimental validation, we will use the discovery of potent covalent CRM1 inhibitors as a specific case study, detailing how our customized, structure-based virtual screening pipeline was utilized to achieve a seamless workflow from computational prediction to biological validation. This section is intended to offer actionable guidance for experimental researchers seeking to leverage these powerful computational tools. Finally, we highlight the limitations and potential pitfalls of this AI engine─concerns that are equally relevant when developing AI-driven covalent docking algorithms. Building on our group's recent benchmarking of AI docking methods, we objectively evaluate current performance and discuss how transformative advances such as AlphaFold3 may reshape the field.

DRHIN: An Integrated and Interactive Web Server for Drug Repositioning

Drug repositioning (DR) identifies new therapeutic uses for approved drugs, reducing development burdens and offering safer treatment options for patients. While high-throughput technologies generate complex, large-scale multiomics data, existing DR tools struggle to comprehensively analyze the resulting biological networks. To address this challenge, we present DRHIN, an integrated, interactive web server for DR over heterogeneous information networks (HINs) using advanced deep learning techniques. DRHIN integrates transcriptomics, proteomics, and microbiome data, incorporating eight biological entities and 19 association types to build diverse HINs and elucidate the underlying molecular mechanisms. It includes 19 state-of-the-art graph representation algorithms, enabling flexible training, comparison, and evaluation of heterogeneous network data. The platform provides a code-free portal supporting three key predictive tasks: discovering drug-disease associations, repurposing existing drugs for new indications, and identifying potential therapies for specific diseases, making analyses accessible and reproducible. Leveraging high-performance computing, DRHIN efficiently processes million-scale networks, ensuring practical applicability in real-world scenarios. The web server is freely accessible at http://drhin.tianshanzw.cn.

A scalable and quantum-accurate foundation model for biomolecular force fields via linearly tensorized quadrangle attention

Accurate atomistic biomolecular simulations are vital for understanding disease mechanisms and drug discovery, yet existing methods struggle to balance quantum-mechanical accuracy with computational scalability. Classical force fields often lack precision, while quantum methods are computationally prohibitive for complex biological systems. Here we show that LiTEN, a scalable equivariant neural network, resolves this dilemma by efficiently modeling complex three- and four-body interactions with linear complexity via Linearly Tensorized Quadrangle Attention. We introduce LiTEN-FF, a foundation model pre-trained on extensive datasets to ensure broad chemical generalization across diverse molecular spaces. We demonstrate that LiTEN achieves state-of-the-art accuracy on standard benchmarks, consistently outperforming leading approaches in both precision and speed. Furthermore, LiTEN-FF enables comprehensive modeling tasks, ranging from geometry optimization to free energy surface construction, with high computational efficiency for large biomolecules. This framework provides a physically grounded, versatile foundation for advanced biomolecular modeling and drug design applications.

Token-Mol 1.0: tokenized drug design with large language models

The integration of large language models (LLMs) into drug design is gaining momentum; however, existing approaches often struggle to effectively incorporate three-dimensional molecular structures. Here, we present Token-Mol, a token-only 3D drug design model that encodes both 2D and 3D structural information, along with molecular properties, into discrete tokens. Built on a transformer decoder and trained with causal masking, Token-Mol introduces a Gaussian cross-entropy loss function tailored for regression tasks, enabling superior performance across multiple downstream applications. The model surpasses existing methods, improving molecular conformation generation by over 10% and 20% across two datasets, while outperforming token-only models by 30% in property prediction. In pocket-based molecular generation, it enhances drug-likeness and synthetic accessibility by approximately 11% and 14%, respectively. Notably, Token-Mol operates 35 times faster than expert diffusion models. In real-world validation, it improves success rates and, when combined with reinforcement learning, further optimizes affinity and drug-likeness, advancing AI-driven drug discovery. In this work the authors present Token-Mol, a token-only 3D drug design model, which deploys the Gaussian cross-entropy (GCE) loss function for regression tasks. It exhibits superior performance in molecular conformation generation, property prediction, and pocket-based generation, thus opening up new avenues for drug design.

A fused deep learning approach to transform drug repositioning

Drug repositioning holds promise for discovering new therapeutic applications for existing drugs, accelerating drug development and reducing associated costs. However, current methodologies encounter difficulties in managing diverse network representations, tackling cold start issues, and handling intrinsic attribute representations. Here we introduce a Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), which integrates knowledge graph embedding, pre-training strategies, and recommendation systems to address these challenges. To overcome the cold start issue, UKEDR utilizes a semantic similarity-driven embedding approach. Our evaluations show that UKEDR performs better than various baselines, including classical machine learning, network-based, and deep learning approaches. In cold start scenarios, it demonstrates an improved capability in handling unseen nodes and generalizing to new compounds. The model also demonstrates strong robustness on imbalanced datasets and shows excellent generalization capabilities in specific drug-centric and disease-centric cold-start scenarios, validating its potential for real-world applications. Drug repositioning offers a promising avenue for accelerating drug development, yet existing methods struggle with network diversity, cold start issues, and intrinsic attribute representation. Here, the authors introduce UKEDR, a deep learning framework that integrates knowledge graph embedding and pre-training strategies to overcome the intractable cold start issue, achieving superior performance and interpretability in drug repurposing.

Enhanced Sampling in the Age of Machine Learning: Algorithms and Applications

Molecular dynamics simulations hold great promise for providing insight into the microscopic behavior of complex molecular systems. However, their effectiveness is often constrained by long timescales associated with rare events. Enhanced sampling methods have been developed to address these challenges, and recent years have seen a growing integration with machine learning techniques. This Review provides a comprehensive overview of how they are reshaping the field, with a particular focus on the data-driven construction of collective variables. Furthermore, these techniques have also improved biasing schemes and unlocked novel strategies via reinforcement learning and generative approaches. In addition to methodological advances, we highlight applications spanning different areas, such as biomolecular processes, ligand binding, catalytic reactions, and phase transitions. We conclude by outlining future directions aimed at enabling more automated strategies for rare-event sampling.

HiCLR: Knowledge-Induced Hierarchical Contrastive Learning with Retrosynthesis Prediction Yields a Reaction Foundation Model

Reaction representation learning is of paramount importance for adopting deep-learning-based chemistry modeling to solve real-world tasks such as synthesis planning. Most prevailing models are prestrained by self-supervised objectives that rely solely on the chemical structure information. Since structurally similar reactions could possess entirely distinct properties (e.g., reaction yields) and the synthesis-related tasks are highly heterogeneous, there are inherent limitations in constructing a foundational reaction model within the existing approaches. To tackle this limitation, we propose HiCLR, a knowledge-induced hierarchical contrastive learning framework for chemical reactions, by introducing relational inductive bias to forge chemically meaningful and generally applicable reaction fingerprints. Critically, the pretraining scheme combining both retrosynthesis prediction and contrastive loss enables HiCLR to tackle generation-based and understanding-based tasks simultaneously. Comprehensive experiments demonstrate that HiCLR successfully organizes the reaction space into hierarchical global semantic clusters, aligned well with prior knowledge. Consequently, HiCLR is the first foundation model that can be broadly applied to various synthesis-related tasks, and it achieves state-of-the-art performance in reaction classification, reaction condition recommendation, reaction yield prediction, synthesis planning, and even molecular property prediction. HiCLR demonstrates clear benefits in incorporating domain knowledge to guide the learning of neural networks, expediting AI-driven advancements in chemistry.

RSGPT: a generative transformer model for retrosynthesis planning pre-trained on ten billion datapoints

Retrosynthesis planning is a crucial task in organic synthesis, and deep-learning methods have enhanced and accelerated this process. With the advancement of the emergence of large language models, the demand for data is rapidly increasing. However, available retrosynthesis data are limited to only millions. Therefore, we pioneer the utilization of the template-based algorithm to generate chemical reaction data, resulting in the production of over 10 billion reaction datapoints. A generative pretrained transformer model is subsequently developed for template-free retrosynthesis planning by pre-training on 10 billion generated data. Inspired by the strategies of large language models, we introduce reinforcement learning to capture the relationships among products, reactants, and templates more accurately. Experiments demonstrate that our model achieves state-of-the-art performance on the benchmark, with a Top-1 accuracy of 63.4%, substantially outperforming previous models. Computer-aided synthesis-planning methods have significantly assisted synthesis planning. In this work, the authors present RSGPT, a generative model pre-trained on ten billion data points, achieving state-of-the-art performance for synthesis planning

LaMGen: LLM-based 3D molecular generation for multi-target drug design

Multi-target drugs hold great promise for treating complex diseases, yet existing methodologies predominantly rely on ligand-based approaches, which lack sufficient biological context and are often confined to specific target pairs, resulting in limited generalizability. Here, we introduce LaMGen, a general-purpose multi-target drug design framework powered by large language models (LLMs). Built on MTD2025, a dataset comprising over 600,000 quantum-accurate molecular conformations and 700,000 multi-target associations, LaMGen directly yields energy-favorable conformations with quantum-level accuracy. The framework integrates ESM-C protein embeddings, rotation-aware ligand tokens, and a TriCoupleAttention module to capture multi-level target–ligand interactions. Across independent benchmarks, LaMGen outperforms diffusion-based model across multiple properties, generating molecules in an average of 0.44 s, while preserving high conformational plausibility. Retrospective analyses demonstrate that LaMGen not only can reproduce molecules identical to known actives, but also consistently produces structurally novel candidates with conserved core scaffolds and superior binding affinities. Designing effective multi-target therapeutics remains a major challenge, as existing ligand- or protein-centric methods struggle to generate biologically contextualized, spatially valid 3D molecules, particularly for triple-target systems. This study introduces LaMGen, an LLM-powered framework that leverages large-scale protein-ligand data and rotation-aware molecular encoding to rapidly produce chemically plausible multi-target candidates, achieving strong zero-shot generalization, superior molecular quality, and robust performance across dual- and triple-target design tasks.

In Silico Design and Evaluation of a CRISPR dCas9 DNMT3A DNMT3L Epigenetic Editing System Targeting the CDKN2A Promoter

CDKN2A (p16) is a tumor suppressor gene whose normal function is to stop the cell cycle from over dividing, allowing cells to enter senescence after completing their function. When the CDKN2A promoter is methylated, the gene is silenced, and cells continue dividing rather than stopping, a mechanism shown in published research to delay cellular senescence and support extended cell culture, with relevance to stem cell research. This project used a CRISPR based dCas9 DNMT3A DNMT3L epigenetic editing system to computationally design, filter, and evaluate candidate single guide RNAs targeting the CDKN2A promoter. Using CHOPCHOP, 284 candidate guides were generated and narrowed to six based on GC content, self-complementarity, and zero perfect match off targets, then independently verified using Cas-OFFinder, resulting in three final candidates with zero off target hits across all tested mismatch levels. The UCSC Genome Browser confirmed that all three final guides fall within a continuous CpG island overlapping active regulatory elements. Structural visualization of published crystal structures (PDB: 4UN3 and 5YX2) illustrated the roles of the targeting and catalytic components of the fusion protein. Methylation efficiency for each guide was estimated by comparison to published experimental results, yielding estimated ranges of 25 to 40 percent, 20 to 35 percent, and 15 to 30 percent for the three respective guides. These estimates require experimental validation through bisulfite sequencing before any conclusions can be drawn about actual silencing capacity. This project demonstrates a complete computational workflow for CRISPR based epigenetic editing design, grounded in published experimental precedent.

Safe and Stable Germline Transmission of MSTN Mutations in Cattle

ABSTRACT With the global population expected to reach 10 billion by 2050, sustainable livestock production is critical. Gene editing of the myostatin (MSTN) gene represents a promising strategy to enhance muscle growth in cattle. In this study, MSTN‐mutated founder (F0) cows were used to generate F1 offspring via ovum pick‐up, in vitro fertilization, and embryo transfer. Four F1 calves were born, all confirmed to be heterozygous for the MSTN mutation. Long‐term monitoring showed normal growth and no visible health abnormalities. Whole‐genome sequencing identified SNPs, INDELs, and structural variants, most with minimal predicted functional effects. Proteomic profiling of Longissimus dorsi muscle quantified 2947 proteins, revealing only subtle expression differences between MSTN‐mutated and wild‐type cattle. These results demonstrate stable inheritance and confirm that MSTN editing does not disrupt genome integrity or protein expression. Overall, our findings support the safety and utility of MSTN gene editing to improve livestock productivity for future food security.

CRISPR/Cas9-mediated targeted mutagenesis of GmMYB100 to increase isoflavone content in soybean seeds